LEXIS CARTER: Open Payments
NPI 1922670389 · NEWPORT, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,907 in 111 payments from 34 companies in 2025. Trend: 2023 $2,529 · 2024 $2,714 · 2025 $1,907
Food & beverage: $1,907
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $217 |
| Otsuka America Pharmaceutical, Inc. | 21 | $178 |
| ABBVIE INC. | 12 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $128 |
| GlaxoSmithKline, LLC. | 7 | $111 |
| Viatris Specialty LLC | 5 | $97 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $80 |
| Mallinckrodt Hospital Products Inc. | 3 | $71 |
| Lilly USA, LLC | 4 | $68 |
| Axsome Therapeutics, Inc. | 3 | $58 |
Products named: REXULTI, CAPLYTA, YUPELRI, TRELEGY ELLIPTA, NEXIUM, Kerendia, FARXIGA, ACTHAR.
Industry payments across TN — which companies pay providers there.
